Brian Kim
Dermatology · Saint Louis, MONPI 1336331826
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Sanofi at 52.1% of the total. Among dermatology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $1812.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$448K
- Sanofi-aventis U.S. LLC$86K
- Pfizer$70K
- LEO Pharma AS$32K
- Regeneron$32K
- Galderma Laboratories, L.p.$28K
- plus $165K from 28 others
Across 114 payments — averaging $13,247 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- LEO Pharma AS$988K
- AbbVie$272K
- Amgen$100K
- Incyte Corporation$65K
- Regeneron$29K
- Pfizer$28K
- plus $28K from 4 others
What the payments were for
- Consulting fees$506,64159%
- Speaking & faculty fees$260,20730%
- Travel & lodging$85,39410%
- Food & beverage$8,7191%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 144 | $448,172 |
| Sanofi-aventis U.S. LLC | 34 | $86,096 |
| Pfizer | 39 | $70,488 |
| LEO Pharma AS | 8 | $32,125 |
| Regeneron | 26 | $31,613 |
| Galderma Laboratories, L.p. | 20 | $27,937 |
| AbbVie | 47 | $24,142 |
| Novartis | 15 | $22,290 |
| Regeneron Healthcare Solutions, Inc. | 35 | $21,290 |
| Eli Lilly | 13 | $18,666 |
| E.r. Squibb & Sons, L.L.C. | 3 | $13,358 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12,938 |
| LEO Pharma Inc. | 19 | $10,198 |
| Almirall LLC | 3 | $9,625 |
| Boehringer Ingelheim | 21 | $6,916 |
| Gilead | 4 | $5,101 |
| Amgen | 7 | $4,667 |
| Janssen Research & Development, LLC | 2 | $4,025 |
| Sanofi US Services Inc. | 1 | $3,820 |
| Astrazeneca UK Limited | 1 | $2,658 |
| Blueprint Medicines Corporation | 1 | $1,925 |
| Lilly USA, LLC | 5 | $1,735 |
| Genentech, Inc. | 1 | $500 |
| UCB, Inc. | 1 | $160 |
| Grifols USA, LLC | 7 | $154 |
| Dermavant Sciences, Inc. | 5 | $100 |
| Incyte Corporation | 4 | $94 |
| GRT US Holding, Inc. | 1 | $69 |
| Johnson & Johnson | 2 | $35 |
| Mirum Pharmaceuticals, Inc. | 1 | $34 |
| Microvention, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Apria Healthcare LLC | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$860,995 in reported general payments places this provider in the 95th percentile of 263 dermatology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 29 | $106,806 |
| XolairOmalizumab | 17 | $60,548 |
| OpzeluraRuxolitinib Phosphate | 17 | $34,431 |
| Butorphanol Tartrate | 34 | $881 |
| Gabapentin | 24 | $184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $500 | $60,54817 claims |
| Incyte CorporationOpzelura | $94 | $34,43117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 dermatology providers in Missouri.
Other dermatology in Saint Louis
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Mary GeorgeSaint Louis$400K
- Duane DilworthSaint Louis$288K
- Jeffrey ReedSaint Louis$170K
- Emily ColeSaint Louis$163K
- Dee GlaserSaint Louis$131K
- Milan AnadkatSaint Louis$129K
- Jason AmatoSaint Louis$45K
- Amy MusiekSaint Louis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.